IPR: A 2nd Bite At The Apple For Hatch-Waxman Litigants
With the advent of inter partes review, Congress authorized a second and parallel adjudicatory proceeding for generic pharmaceutical companies to challenge the validity of Orange Book-listed patents.[1] The first option, of...To view the full article, register now.
Already a subscriber? Click here to view full article